0001193125-26-213424
SEC filingRevenue grew to $26.0M with a 55.5% gross margin, but net loss widened to $21.3M due to operating investments and non-cash losses.
Revenue for Q1 FY2026 was $26.0 million, reflecting strong demand for both instruments and consumables. The increase was primarily due to growth in the installed base, which drove higher consumables revenue, particularly multiplex panel kits. Additionally, TAP services and instrument maintenance service agreements contributed to revenue growth.
Gross profit was $14.5 million, representing a gross margin of 55.5%. The margin improvement was driven by increased sales volume of both instruments and consumables, partially offset by realization of manufacturing efficiencies as consumable production scaled. The favorable mix shift toward consumables also supported margin expansion.
Operating income was -$12.3 million, reflecting significant investments in research and development and selling, general and administrative expenses. Net income was -$21.3 million, which included non-cash losses from convertible note remeasurement. Diluted EPS was -$1.74.
R&D and SG&A expenses increased substantially due to headcount growth and costs associated with becoming a public company. Management expects R&D expense to increase further in absolute dollars as the company continues to invest in product development and clinical programs.
Management expects continued investment in R&D, manufacturing capacity, and commercial infrastructure, which will keep operating losses elevated in the near term. Key risks include reliance on government research funding, competition from established proteomics players, and potential supply chain disruptions. The company is developing the ARGO HT/DX instrument for FDA submission in 2027, which could open the clinical diagnostics market but adds regulatory and execution risk.